NCT07186387

Study of LW402 in Moderate-to-Severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of LW402 in Patients With Moderate-to-Severe Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 144 (actual)
• Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, randomized, double blind, placebo-controlled phase 2 study to evaluate the efficacy, safety, PK and PD ofLW402 in patients with moderate-to-severe atopic dermatitis.

Detailed description

The study consists of an up-to-4-week screening period, a 12-week double-blind treatment period and a 4-week safety follow-up period.

Conditions

• Atopic Dermatitis (AD)

Interventions

Type	Name	Description
DRUG	LW402	LW402 tablets
DRUG	LW402 placebo	LW402 placebo tablets

Timeline

• Start date: 2023-05-11
• Primary completion: 2024-09-25
• Completion: 2025-02-13
• First posted: 2025-09-22
• Last updated: 2025-10-02

Locations

1 site across 1 country: China